Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Jefferies Downgrades Mesoblast to Hold

Jefferies Downgrades Mesoblast to Hold

Jefferies analyst David Stanton downgrades Mesoblast (NASDAQ:MESO) from Buy to Hold.

byBenzinga Newsdesk

December 6, 2022

1 minute read

Jefferies analyst David Stanton downgrades Mesoblast (NASDAQ:MESO) from Buy to Hold.

Citigroup Initiates Coverage On Molson Coors Beverage with Neutral Rating, Announces Price Target of $55

By Benzinga Newsdesk

February 17, 6:52 AM

Citigroup analyst Filippo Falorni initiates coverage on Molson Coors Beverage (NYSE:TAP) with a Neutral rating and announces Price Target of $55.

TAP

News
Tech

Elon Musk Comes Up With Tweaks That Could Better Concorde Fuel Efficiency, Performance — Can The Supersonic Jet Be Revived?

By Anan Ashraf

October 31, 2:28 AM

CEO of Electric Vehicle giant Tesla Inc (NASDAQ:TSLA) and rocket manufacturing company SpaceX Elon Musk on Monday recommended…

TSLA

JPMorgan’s Jeffrey Epstein Saga Ends with $75M Settlement

By Anusuya Lahiri

September 26, 1:17 PM

JPMorgan Chase (NYSE: JPM) has reached a $75 million settlement with the U.S.

Reported Late Monday March 13, Everest Medicines Announces Partner Calliditas Therapeutics Reports Topline Results From Phase 3 NefIgArd Trial Evaluating Nefecon In IgA Nephropathy; Trial Primary Endpoint Was Met With Nefecon

By Happy Mohamed

March 14, 1:10 AM

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that its partner Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX)))) ("Calliditas") reported

CALT

Jefferies Downgrades Mesoblast to Hold

Related Posts

Citigroup Initiates Coverage On Molson Coors Beverage with Neutral Rating, Announces Price Target of $55

Elon Musk Comes Up With Tweaks That Could Better Concorde Fuel Efficiency, Performance — Can The Supersonic Jet Be Revived?

JPMorgan’s Jeffrey Epstein Saga Ends with $75M Settlement

Reported Late Monday March 13, Everest Medicines Announces Partner Calliditas Therapeutics Reports Topline Results From Phase 3 NefIgArd Trial Evaluating Nefecon In IgA Nephropathy; Trial Primary Endpoint Was Met With Nefecon